The global vaginal antifungals market enjoys a valuation of US$ 1.09 Billion in 2022, and it is further projected to expand at a CAGR of 4.5% over the forecasted years. According to a recent study by Future Market Insights, Polygenes are leading the market with a share of about 49.0% in the year 2022, within the global market.
Market Outlook
| Data Points | Market Insights |
|---|---|
| Market Value 2022 | US$ 1.09 Billion |
| Market Value 2033 | US$ 1.76 Billion |
| CAGR 2023 to 2033 | 4.5% |
| Market Share of Top 5 Countries | 61.7% |
| Key Market Players | Pfizer Inc., Bausch Health Companies Inc., ANI Pharmaceuticals, Inc., Hikma Pharmaceuticals Plc, Lupin Limited, Mycovia Pharmaceuticals, Inc., Glenmark Pharmaceuticals Limited, Unique Pharmaceuticals, PEPTONIC Medical AB, Aurobindo Pharma Limited, Dr. Reddy's Laboratories, SCYNEXIS Inc., Basilea Pharmaceutica Ltd., Astellas Pharma Inc., Grupo Ferrer Internacional, S.A.Pacgen Life Science Corporation, NovaDigm Therapeutics, Inc., Cidara Therapeutics, Inc., Amplyx Pharmaceuticals Inc. |
The signs of vaginal fungi infections include bloating near the vagina, burning when urinating, whitish-grey and clumpy vaginal discharge, and many others. Another name for vaginal yeast infection is candidiasis. Bacteria and a small number of yeast cells make up a healthy vagina, but when the ratio of bacteria to yeast changes, the yeast cells have the potential to multiply, which can further cause extreme itching, swelling, and irritation.
Antifungal medications prevent fungal infections from occurring by limiting the growth of fungus microorganisms on the host cell. As a result, the market is being favourably impacted by the availability of a variety of antifungal medications for the treatment of fungal infections as well as availability of over-the-counter medications.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The global sales of the market are anticipated to rise at a CAGR of 4.5% between 2023 and 2033, owing to the rising prevalence of vaginal infectious disease.
The global vaginal antifungals market holds around 7.4% share of the overall global antifungals drug market with a value of around US$ 14.74 Billion, in 2022.
Vulvovaginal candidiasis (VVC), which mainly affects immunocompetent childbearing age women, frequently affects the lower female genital tract. Candida albicans is the pathogenic yeast that is most commonly linked to this fungus infection, excluding other non-albicans species.
Significant number of women, according to various scientists, have candida in their vaginas without exhibiting any signs. If the vaginal environment changes to favour Candida development, an infection may result. Hormones, medications, and immune system changes can all trigger infection. Additionally, among women of reproductive age, infectious organisms most frequently cause vulvovaginitis, or inflammation of the vulva and vagina. Candida vulvovaginitis is the root cause of around one-third of these instances.
The VVC emergence can be influenced by a variety of lifestyle factors. Although some studies suggest that excessive use of antibiotics and uncontrolled diabetes in women results in the vaginal fungal infections. Thus, the rising prevalence of diabetic patients in women is propelling the market.
Although, the market is being constrained by the reality that despite how many topical have been developed by the manufacturers, they are ineffective because they do not penetrate the skin well enough. However, the creation of novel products to enhance delivery, absorption, retention, and bioabsorbility in vulvovaginal tissue provides a significant market opportunity for manufacturers and drug developers.
Owing to the above-mentioned factors, the global market is expected to grow at a prominent pace, and reach a valuation of around US$ 1.76 Billion during the year 2033.
The market is anticipated to expand due to a rise in the vulvovaginal candidiasis in pregnant women and risk of fungal infection in diabetic patients.
Worldwide, pregnant women are affected by vulvovaginal candidiasis (VVC), a yeast infection of the vulva brought on by species of Candida. Due to a rise in the level of estrogen, which makes it easier for yeast to colonise the vagina pregnant women are more susceptible to developing VVC.
Similarly, antifungals are in high demand due to an increase in the danger of fungal infections in diabetic patients. Diabetes Mellitus has been linked to a number of health problems in women, including yeast infection. Diabetes, or unregulated blood glucose levels, can cause yeast overgrowth in warm and moist regions of the body, especially the vagina.
As a result, the increased risk of fungal infection in diabetes patients, as well as the desire for curative medication, are driving market expansion.
Principal Consultant
Due to medication side effects and a reduced detection rate as a result of asymptomatic fungal infections, the market is anticipated to slow down.
There is a need for the vaginal infections to be treated because the prevalence of fungi-related diseases is increasing globally. The absence of infection detection, however, is the main hindrance to market expansion. For instance, according to the Centers for Disease Control and Prevention, many fungi illnesses go undetected because of their vague symptoms. In addition, according to the article "Patient education: Bacterial vaginosis (Beyond the Basics)" in UpToDate 2023, around 50 to 75 percent of persons with BV have no symptoms. Hence, the lower detection rate is leading to a limited treatment rate for fungal infections, which is hampering the market.
Similar to this, the market is being gradually restrained by the negative effects of the medication used to treat vaginal fungal infections. For instance, vulvovaginal candidiasis is more common in pregnant women, making them essential for the treatment. Contrarily, animal studies by SCYNEXIS, Inc. suggest that administering the antifungal medication BREXAFEMME to pregnant women could damage the foetus. These serious drug side effects are preventing the industry from expanding. Additionally, diarrhoea, nausea, abdominal pain, and vomiting were the most frequent adverse reactions seen in clinical studies (incidence 2%). As a consequence, the market's development is constrained by the potent side effects of the drugs used to treat a fungus infection.
The USA dominates the global market with a total market share of around 27.0% in 2022, and the same rate of growth is anticipated to continue throughout the forecast period.
Rising prevalence of trichomoniasis in the country is supporting to the market growth for the vaginal antifungals.
Trichomoniasis can make it more probable for people to contract or spread HIV, and it increases the likelihood that women infected with the condition will deliver their babies prematurely and with low birth weights.
Therefore, with the increasing burden of fungal infection diseases, the demand for cure treatments is increasing, which is raising the market.
China has a market share of 12.8% in the global vaginal antifungals market in 2022 due to the upsurge in the high quality health care service in by the government.
As the cornerstone of integrated care, the Chinese government began to investigate the hierarchical diagnostic and treatment system. An institutional innovation in health care reform is the development of medical alliances, which enables hospitals and primary health care (PHC) facilities to collaborate closely to offer disease prevention, treatment, and rehabilitation services across the life course. By the end of 2019, China have created 12,000 medical alliances in order to mobilise high-quality healthcare services from public hospitals to PHC facilities.
Germany holds a market share of 7.6% in 2022 in the global vaginal antifungals market, owing to the government flutter to combat the infectious diseases.
Since 2016, Germany has been a steadfast supporter of Global Antibiotic Research and Development Partnership (GARDP) and has taken the lead in initiatives to combat antibiotic resistance. German government continues to be the largest contributor to GARDP with the new financing, increasing the entirety of its expenditures to EUR 116 million. Over the following five years (2023-2027), the German Federal Ministry of Education and Research pledged a further EUR 50 million in funds for the GARDP. The German financing will enable GARDP to develop novel antibiotic-resistant sickness therapies and ensure that everyone who requires them has access to them.
As a result, increased government funding for antibiotic resistance drugs is propelling the country's vaginal antifungals market.
India has a market share of 8.6% in the global vaginal antifungals market in 2022 due to the rising prevalence of vulvovaginal candidiasis.
Vulvovaginal candidiasis (VVC) is a clinical disease that is frequently seen in India. At least one episode of VVC occurs in at least three-fourths of all women's lifetimes. According to a study published in the Indian Journal of Obstetrics and Gynaecology Research, titled Vulvovaginal Candidiasis: Epidemiology, Treatment, and Prevention Strategies, the prevalence of VVC in India ranges from 10 to 35%.
So, topical treatments for short courses are useful in treating straightforward VVC. In 80%–90% of patients who complete therapy, azole treatment relieves symptoms and produces negative cultures according to CDC 2021. The success of oral and topical therapies for the VVC has led to an increase in the demand for antifungals.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Polygenes are expected to give high growth to the market and holding around 49.0% market share in 2022.
All common fungi that cause systemic infection, including species of Candida, Aspergillus, Mucor, and Cryptococcus, are responsive to amphotericin (belongs to the polyene class of antifungals). For infections caused by the aforementioned species, polyenes are very effective, which is leading to their high adoption. These medications are thought to be the most affordable, secure, and low-toxic antifungal agents available. Therefore, the demand is increasing because polyenes have fewer negative effects.
Topical administration is mostly preferred by the healthcare professional for the treatment purpose. It has a market share of 73.1% in the global market in 2022.
Due to their tailored therapy and limited adverse effects, topical fungal therapies are typically favoured. Due to their unique functional and structural characteristics, advanced topical transporters get beyond biopharmaceutical issues with traditional drug delivery systems, such as poor retention and low bioavailability. Additionally, continuous usage of antifungal medications has the potential to have negative side effects. In order to address this problem, patient cooperation is directed towards topical infection treatment. As a result, the market leader is the topical treatment category.
Bacterial vaginosis holds the market share of 44.9% during the year 2022.
A bacterial imbalance results in overgrowth of bacteria, which leads to bacterial vaginosis (BV), a common vaginal infection. The risk of bacterial vaginosis in pregnant women is increasing, which is also driving market expansion. Preterm birth, early miscarriage, postpartum endometritis, low birth weight, has been observed in women with bacterial vaginosis during pregnancy.
Gynaecology Clinics hold a market share of 41.4% during the year 2022. It is due to the high priority for the gynaecology clinics by the patients. The availability of specialised clinicians and high-tech treatment equipment attracts people to gynaecology clinics. Furthermore, the rising prevalence of vaginal infectious illnesses, combined with increased investment in infrastructure development, is increasing the usage of gynaecology clinics.
Leading companies in the global vaginal antifungals market are seeking for possibilities such as regional expansion to improve their market share. Furthermore, in order to boost their market presence, local rising companies are employing different methods such as mergers, cooperation, acquisition, agreement, and product launches and development in the vaginal antifungals market.
Similarly, recent developments related to companies manufacturing vaginal antifungals products have been tracked by the team at Future Market Insights. These are available in the full report.
| Attribute | Details |
|---|---|
| Forecast Period | 2018 to 2022 |
| Historical Data Available for | 2023 to 2033 |
| Market Analysis | US$ Million for Value |
| Key Regions Covered | North America; Latin America; Europe; South Asia; East Asia; Oceania; and the Middle East & Africa |
| Key Countries Covered | The USA, Canada, Brazil, Mexico, Argentina, The United kingdom, Germany, Italy, Russia, Spain, France, Benelux, India, Thailand, Indonesia, Malaysia, Japan, China, South Korea, Australia, New Zealand, Türkiye, GCC Countries and South Africa |
| Key Market Segments Covered | Product, Route of Administration, Indication, Distribution Channel, and Region |
| Key Companies Profiled | Pfizer Inc.; Bausch Health Companies Inc; ANI Pharmaceuticals, Inc.; Hikma Pharmaceuticals Plc; Lupin Limited; Mycovia Pharmaceuticals, Inc.; Glenmark Pharmaceuticals Limited; GSK plc.; Aurobindo Pharma Limited; Dr. Reddy's Laboratories; SCYNEXIS, Inc.; Basilea Pharmaceutica Ltd.; Astellas Pharma Inc.; Grupo Ferrer Internacional, S.A.; Pacgen Life Science Corporation; NovaDigm Therapeutics, Inc.; Cidara Therapeutics, Inc.; Amplyx Pharmaceuticals Inc. |
| Report Coverage | Market Forecast, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, Strategic Growth Initiatives |
| Pricing | Available upon Request |
The CAGR of the market is 4.5% through 2033.
The global market size to reach US$ 1.76 Billion by 2033.
With a market share of 27.0%, the United States governs the global market.
China possesses a 12.8% market share in the market.
The market has slowed notably owing to side effects from drugs and a lower identification rate as a consequence of asymptomatic fungal infections.
Due to a spike in vulvovaginal candidiasis in pregnant ladies and the potential of fungal infection in diabetics, the market is set to expand.
1. Executive Summary | Vaginal Antifungals Market 1.1. Global Market Outlook 1.2. Demand Side Trends 1.3. Supply Side Trends 1.4. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 2.3. Inclusions and Exclusions 3. Key Market Trends 3.1. Key Trends Impacting the Market 3.2. Product Innovation / Development Trends 4. Value Added Insights 4.1. Product Adoption / Usage Analysis 4.2. Recent Product Launches 4.3. Disease Epidemiology 4.4. Patient Treatment Regime 4.5. Pipeline Assessment 4.6. Regulatory Scenario 4.7. PESTLE Analysis 4.8. Porter’s Analysis 4.9. Value Chain Analysis 5. Market Background 5.1. Macro-Economic Factors 5.1.1. Global GDP Growth Outlook 5.1.2. Global Healthcare Expenditure Outlook 5.1.3. Global Antifungal Drugs Market Outlook 5.2. Forecast Factors - Relevance & Impact 5.2.1. Key Player’s Historic Growth 5.2.2. New Product Launches / Approvals 5.2.3. Rising Prevalence of Vaginal Infectious Diseases 5.2.4. Demand for Minimally Invasive Treatment 5.2.5. High Incidence of Trichomoniasis 5.2.6. Growing Investment in Healthcare Expenditure 5.2.7. Government Support for Research and Developments 5.3. Dynamics 5.3.1. Drivers 5.3.2. Restraints 5.3.3. Opportunity Analysis 6. COVID-19 Crisis – Impact Assessment 6.1. COVID-19 and Impact Analysis 6.1.1. By Product 6.1.2. By Route of Administration 6.1.3. By Indication 6.1.4. By Distribution Channel 6.1.5. By Region 6.2. 2022 Market Scenario 7. Global Market Demand (in Value or Size in US$ Million) Analysis 2018 to 2022 and Forecast, 2023 to 2033 7.1. Historical Market Value (US$ Million) Analysis, 2018 to 2022 7.2. Current and Future Market Value (US$ Million) Projections, 2023 to 2033 7.2.1. Y-o-Y Growth Trend Analysis 7.2.2. Absolute $ Opportunity Analysis 8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Product 8.1. Introduction / Key Findings 8.2. Historical Market Size (US$ Million) Analysis By Product, 2018 to 2022 8.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Product, 2023 to 2033 8.3.1. Polyenes 8.3.2. Azoles 8.3.3. Allylamines 8.3.4. Echinocandins 8.3.5. Others 8.4. Market Attractiveness Analysis By Product 9. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Route of Administration 9.1. Introduction / Key Findings 9.2. Historical Market Size (US$ Million) Analysis By Route of Administration, 2018 to 2022 9.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Route of Administration, 2023 to 2033 9.3.1. Oral 9.3.2. Topical 9.4. Market Attractiveness Analysis By Route of Administration 10. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Indication 10.1. Introduction / Key Findings 10.2. Historical Market Size (US$ Million) Analysis By Indication, 2018 to 2022 10.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Indication, 2023 to 2033 10.3.1. Bacterial Vaginosis 10.3.2. Candidiasis 10.3.3. Trichomoniasis 10.3.4. Others 10.4. Market Attractiveness Analysis By Route of Administration 11. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel 11.1. Introduction / Key Findings 11.2. Historical Market Size (US$ Million) Analysis By Distribution Channel, 2018 to 2022 11.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Distribution Channel, 2023 to 2033 11.3.1. Hospital Pharmacies 11.3.2. Supermarkets/hypermarkets 11.3.3. Online Pharmacies 11.3.4. Gynaecology Clinics 11.3.5. Others 11.4. Market Attractiveness Analysis By Distribution Channel 12. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, by Region 12.1. Introduction 12.2. Historical Market Size (US$ Million) Analysis By Region, 2018 to 2022 12.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Region, 2023 to 2033 12.3.1. North America 12.3.2. Latin America 12.3.3. Europe 12.3.4. South Asia 12.3.5. East Asia 12.3.6. Oceania 12.3.7. Middle East and Africa (Middle East and Africa) 12.4. Market Attractiveness Analysis By Region 13. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033 13.1. Introduction 13.2. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2018 to 2022 13.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033 13.3.1. By Country 13.3.1.1. USA 13.3.1.2. Canada 13.3.2. By Product 13.3.3. By Route of Administration 13.3.4. By Indication 13.3.5. By Distribution Channel 13.4. Market Attractiveness Analysis 13.4.1. By Country 13.4.2. By Product 13.4.3. By Route of Administration 13.4.4. By Indication 13.4.5. By Distribution Channel 13.5. Country Level Analysis & Forecast 13.5.1. USA Market Analysis 13.5.1.1. . Introduction 13.5.1.2. Market Analysis and Forecast by Market Taxonomy 13.5.1.2.1. By Product 13.5.1.2.2. By Route of Administration 13.5.1.2.3. By Indication 13.5.1.2.4. By Distribution Channel 13.5.2. Canada Market Analysis 13.5.2.1. Introduction 13.5.2.2. Market Analysis and Forecast by Market Taxonomy 13.5.2.2.1. By Product 13.5.2.2.2. By Route of Administration 13.5.2.2.3. By Indication 13.5.2.2.4. By Distribution Channel 13.6. Market Trends 13.7. Key Market Participants - Intensity Mapping 13.8. Drivers and Restraints - Impact Analysis 14. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033 14.1. Introduction 14.2. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2018 to 2022 14.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033 14.3.1. By Country 14.3.1.1. Brazil 14.3.1.2. Mexico 14.3.1.3. Argentina 14.3.1.4. Rest of Latin America 14.3.2. By Product 14.3.3. By Route of Administration 14.3.4. By Indication 14.3.5. By Distribution Channel 14.4. Market Attractiveness Analysis 14.4.1. By Country 14.4.2. By Product 14.4.3. By Route of Administration 14.4.4. By Distribution Channel 14.5. Country Level Analysis & Forecast 14.5.1. Brazil Market Analysis 14.5.1.1. . Introduction 14.5.1.2. Market Analysis and Forecast by Market Taxonomy 14.5.1.2.1. By Product 14.5.1.2.2. By Route of Administration 14.5.1.2.3. By Indication 14.5.1.2.4. By Distribution Channel 14.5.2. Mexico Market Analysis 14.5.2.1. Introduction 14.5.2.2. Market Analysis and Forecast by Market Taxonomy 14.5.2.2.1. By Product 14.5.2.2.2. By Route of Administration 14.5.2.2.3. By Indication 14.5.2.2.4. By Distribution Channel 14.5.3. Argentina Market Analysis 14.5.3.1. Introduction 14.5.3.2. Market Analysis and Forecast by Market Taxonomy 14.5.3.2.1. By Product 14.5.3.2.2. By Route of Administration 14.5.3.2.3. By Indication 14.5.3.2.4. By Distribution Channel 14.6. Market Trends 14.7. Key Market Participants - Intensity Mapping 14.8. Drivers and Restraints - Impact Analysis 15. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033 15.1. Introduction 15.2. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2018 to 2022 15.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033 15.3.1. By Country 15.3.1.1. Germany 15.3.1.2. France 15.3.1.3. Italy 15.3.1.4. United kingdom 15.3.1.5. Spain 15.3.1.6. Russia 15.3.1.7. BENELUX 15.3.1.8. Nordic Countries 15.3.1.9. Rest of Europe 15.3.2. By Product 15.3.3. By Route of Administration 15.3.4. By Indication 15.3.5. By Distribution Channel 15.4. Market Attractiveness Analysis 15.4.1. By Country 15.4.2. By Product 15.4.3. By Route of Administration 15.4.4. By Indication 15.4.5. By Distribution Channel 15.5. Country Level Analysis & Forecast 15.5.1. Germany Market Analysis 15.5.1.1. . Introduction 15.5.1.2. Market Analysis and Forecast by Market Taxonomy 15.5.1.2.1. By Product 15.5.1.2.2. By Route of Administration 15.5.1.2.3. By Indication 15.5.1.2.4. By Distribution Channel 15.5.2. France Market Analysis 15.5.2.1. Introduction 15.5.2.2. Market Analysis and Forecast by Market Taxonomy 15.5.2.2.1. By Product 15.5.2.2.2. By Route of Administration 15.5.2.2.3. By Indication 15.5.2.2.4. By Distribution Channel 15.5.3. Italy Market Analysis 15.5.3.1. Introduction 15.5.3.2. Market Analysis and Forecast by Market Taxonomy 15.5.3.2.1. By Product 15.5.3.2.2. By Route of Administration 15.5.3.2.3. By Indication 15.5.3.2.4. By Distribution Channel 15.5.4. United kingdom Market Analysis 15.5.4.1. . Introduction 15.5.4.2. Market Analysis and Forecast by Market Taxonomy 15.5.4.2.1. By Product 15.5.4.2.2. By Route of Administration 15.5.4.2.3. By Indication 15.5.4.2.4. By Distribution Channel 15.5.5. Spain Market Analysis 15.5.5.1. . Introduction 15.5.5.2. Market Analysis and Forecast by Market Taxonomy 15.5.5.2.1. By Product 15.5.5.2.2. By Route of Administration 15.5.5.2.3. By Indication 15.5.5.2.4. By Distribution Channel 15.5.6. Russia Market Analysis 15.5.6.1. . Introduction 15.5.6.2. Market Analysis and Forecast by Market Taxonomy 15.5.6.2.1. By Product 15.5.6.2.2. By Route of Administration 15.5.6.2.3. By Indication 15.5.6.2.4. By Distribution Channel 15.5.7. Nordic Countries Market Analysis 15.5.7.1. . Introduction 15.5.7.2. Market Analysis and Forecast by Market Taxonomy 15.5.7.2.1. By Product 15.5.7.2.2. By Route of Administration 15.5.7.2.3. By Indication 15.5.7.2.4. By Distribution Channel 15.5.8. BENELUX Market Analysis 15.5.8.1. . Introduction 15.5.8.2. Market Analysis and Forecast by Market Taxonomy 15.5.8.2.1. By Product 15.5.8.2.2. By Route of Administration 15.5.8.2.3. By Indication 15.5.8.2.4. By Distribution Channel 15.6. Market Trends 15.7. Key Market Participants - Intensity Mapping 15.8. Drivers and Restraints - Impact Analysis 16. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033 16.1. Introduction 16.2. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2018 to 2022 16.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033 16.3.1. By Country 16.3.1.1. India 16.3.1.2. Thailand 16.3.1.3. Indonesia 16.3.1.4. Malaysia 16.3.1.5. Rest of South Asia 16.3.2. By Product 16.3.3. By Route of Administration 16.3.4. By Indication 16.3.5. By Distribution Channel 16.4. Market Attractiveness Analysis 16.4.1. By Country 16.4.2. By Product 16.4.3. By Route of Administration 16.4.4. By Indication 16.4.5. By Distribution Channel 16.5. Country Level Analysis & Forecast 16.5.1. India Market Analysis 16.5.1.1. . Introduction 16.5.1.2. Market Analysis and Forecast by Market Taxonomy 16.5.1.2.1. By Product 16.5.1.2.2. By Route of Administration 16.5.1.2.3. By Indication 16.5.1.2.4. By Distribution Channel 16.5.2. Thailand Market Analysis 16.5.2.1. . Introduction 16.5.2.2. Market Analysis and Forecast by Market Taxonomy 16.5.2.2.1. By Product 16.5.2.2.2. By Route of Administration 16.5.2.2.3. By Indication 16.5.2.2.4. By Distribution Channel 16.5.3. Indonesia Market Analysis 16.5.3.1. Introduction 16.5.3.2. Market Analysis and Forecast by Market Taxonomy 16.5.3.2.1. By Product 16.5.3.2.2. By Route of Administration 16.5.3.2.3. By Indication 16.5.3.2.4. By Distribution Channel 16.5.4. Malaysia Market Analysis 16.5.4.1. Introduction 16.5.4.2. Market Analysis and Forecast by Market Taxonomy 16.5.4.2.1. By Product 16.5.4.2.2. By Route of Administration 16.5.4.2.3. By Indication 16.5.4.2.4. By Distribution Channel 16.6. Market Trends 16.7. Key Market Participants - Intensity Mapping 16.8. Drivers and Restraints - Impact Analysis 17. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033 17.1. Introduction 17.2. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2018 to 2022 17.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033 17.3.1. By Country 17.3.1.1. China 17.3.1.2. Japan 17.3.1.3. South Korea 17.3.2. By Product 17.3.3. By Route of Administration 17.3.4. By Indication 17.3.5. By Distribution Channel 17.4. Market Attractiveness Analysis 17.4.1. By Country 17.4.2. By Product 17.4.3. By Route of Administration 17.4.4. By Indication 17.4.5. By Distribution Channel 17.5. Country Level Analysis & Forecast 17.5.1. China Market Analysis 17.5.1.1. . Introduction 17.5.1.2. Market Analysis and Forecast by Market Taxonomy 17.5.1.2.1. By Product 17.5.1.2.2. By Route of Administration 17.5.1.2.3. By Indication 17.5.1.2.4. By Distribution Channel 17.5.2. Japan Market Analysis 17.5.2.1. Introduction 17.5.2.2. Market Analysis and Forecast by Market Taxonomy 17.5.2.2.1. By Product 17.5.2.2.2. By Route of Administration 17.5.2.2.3. By Indication 17.5.2.2.4. By Distribution Channel 17.5.3. South Korea Market Analysis 17.5.3.1. Introduction 17.5.3.2. Market Analysis and Forecast by Market Taxonomy 17.5.3.2.1. By Product 17.5.3.2.2. By Route of Administration 17.5.3.2.3. By Indication 17.5.3.2.4. By Distribution Channel 17.6. Market Trends 17.7. Key Market Participants - Intensity Mapping 17.8. Drivers and Restraints - Impact Analysis 18. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033 18.1. Introduction 18.2. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2018 to 2022 18.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033 18.3.1. By Country 18.3.1.1. Australia 18.3.1.2. New Zealand 18.3.2. By Product 18.3.3. By Route of Administration 18.3.4. By Indication 18.3.5. By Distribution Channel 18.4. Market Attractiveness Analysis 18.4.1. By Country 18.4.2. By Product 18.4.3. By Route of Administration 18.4.4. By Indication 18.4.5. By Distribution Channel 18.5. Country Level Analysis & Forecast 18.5.1. Australia Market Analysis 18.5.1.1. . Introduction 18.5.1.2. Market Analysis and Forecast by Market Taxonomy 18.5.1.2.1. By Product 18.5.1.2.2. By Route of Administration 18.5.1.2.3. By Indication 18.5.1.2.4. By Distribution Channel 18.5.2. New Zealand Market Analysis 18.5.2.1. Introduction 18.5.2.2. Market Analysis and Forecast by Market Taxonomy 18.5.2.2.1. By Product 18.5.2.2.2. By Route of Administration 18.5.2.2.3. By Indication 18.5.2.2.4. By Distribution Channel 18.6. Market Trends 18.7. Key Market Participants - Intensity Mapping 18.8. Drivers and Restraints - Impact Analysis 19. Middle East and Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033 19.1. Introduction 19.2. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2018 to 2022 19.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033 19.3.1. By Country 19.3.1.1. GCC Countries 19.3.1.2. Türkiye 19.3.1.3. Northern Africa 19.3.1.4. South Africa 19.3.1.5. Rest of Middle East and Africa 19.3.2. By Product 19.3.3. By Route of Administration 19.3.4. By Indication 19.3.5. By Distribution Channel 19.4. Market Attractiveness Analysis 19.4.1. By Country 19.4.2. By Product 19.4.3. By Route of Administration 19.4.4. By Indication 19.4.5. By Distribution Channel 19.5. Country Level Analysis & Forecast 19.5.1. GCC Countries Market Analysis 19.5.1.1. . Introduction 19.5.1.2. Market Analysis and Forecast by Market Taxonomy 19.5.1.2.1. By Product 19.5.1.2.2. By Route of Administration 19.5.1.2.3. By Indication 19.5.1.2.4. By Distribution Channel 19.5.2. Türkiye Market Analysis 19.5.2.1. Introduction 19.5.2.2. Market Analysis and Forecast by Market Taxonomy 19.5.2.2.1. By Product 19.5.2.2.2. By Route of Administration 19.5.2.2.3. By Indication 19.5.2.2.4. By Distribution Channel 19.5.3. Northern Africa Market Analysis 19.5.3.1. Introduction 19.5.3.2. Market Analysis and Forecast by Market Taxonomy 19.5.3.2.1. By Product 19.5.3.2.2. By Route of Administration 19.5.3.2.3. By Indication 19.5.3.2.4. By Distribution Channel 19.5.4. South Africa Market Analysis 19.5.4.1. Introduction 19.5.4.2. Market Analysis and Forecast by Market Taxonomy 19.5.4.2.1. By Product 19.5.4.2.2. By Route of Administration 19.5.4.2.3. By Indication 19.5.4.2.4. By Distribution Channel 19.6. Market Trends 19.7. Key Market Participants - Intensity Mapping 19.8. Drivers and Restraints - Impact Analysis 20. Market Structure Analysis 20.1. Market Analysis by Tier of Companies 20.2. Market Share Analysis of Top Players 20.3. Market Presence Analysis 21. Competition Analysis 21.1. Competition Dashboard 21.2. Branding and Promotional Strategies, By Key Players 21.3. Key Development Analysis 21.4. Competition Deep Dive 21.4.1. Pfizer Inc. 21.4.1.1. Overview 21.4.1.2. Product Portfolio 21.4.1.3. Key Financials 21.4.1.4. SWOT Analysis 21.4.1.5. Key Developments 21.4.1.6. Sales Footprint 21.4.1.7. Strategy Overview 21.4.1.7.1. Marketing Strategy 21.4.1.7.2. Product Strategy 21.4.1.7.3. Channel Strategy 21.4.2. Bausch Health Companies Inc 21.4.2.1. Overview 21.4.2.2. Product Portfolio 21.4.2.3. Key Financials 21.4.2.4. SWOT Analysis 21.4.2.5. Key Developments 21.4.2.6. Sales Footprint 21.4.2.7. Strategy Overview 21.4.2.7.1. Marketing Strategy 21.4.2.7.2. Product Strategy 21.4.2.7.3. Channel Strategy 21.4.3. ANI Pharmaceuticals, Inc. 21.4.3.1. Overview 21.4.3.2. Product Portfolio 21.4.3.3. Key Financials 21.4.3.4. SWOT Analysis 21.4.3.5. Key Developments 21.4.3.6. Sales Footprint 21.4.3.7. Strategy Overview 21.4.3.7.1. Marketing Strategy 21.4.3.7.2. Product Strategy 21.4.3.7.3. Channel Strategy 21.4.4. Hikma Pharmaceuticals Plc 21.4.4.1. Overview 21.4.4.2. Product Portfolio 21.4.4.3. Key Financials 21.4.4.4. SWOT Analysis 21.4.4.5. Key Developments 21.4.4.6. Sales Footprint 21.4.4.7. Strategy Overview 21.4.4.7.1. Marketing Strategy 21.4.4.7.2. Product Strategy 21.4.4.7.3. Channel Strategy 21.4.5. Lupin Limited 21.4.5.1. Overview 21.4.5.2. Product Portfolio 21.4.5.3. Key Financials 21.4.5.4. SWOT Analysis 21.4.5.5. Key Developments 21.4.5.6. Sales Footprint 21.4.5.7. Strategy Overview 21.4.5.7.1. Marketing Strategy 21.4.5.7.2. Product Strategy 21.4.5.7.3. Channel Strategy 21.4.6. Mycovia Pharmaceuticals, Inc. 21.4.6.1. Overview 21.4.6.2. Product Portfolio 21.4.6.3. Key Financials 21.4.6.4. SWOT Analysis 21.4.6.5. Key Developments 21.4.6.6. Sales Footprint 21.4.6.7. Strategy Overview 21.4.6.7.1. Marketing Strategy 21.4.6.7.2. Product Strategy 21.4.6.7.3. Channel Strategy 21.4.7. Glenmark Pharmaceuticals Limited 21.4.7.1. Overview 21.4.7.2. Product Portfolio 21.4.7.3. Key Financials 21.4.7.4. SWOT Analysis 21.4.7.5. Key Developments 21.4.7.6. Sales Footprint 21.4.7.7. Strategy Overview 21.4.7.7.1. Marketing Strategy 21.4.7.7.2. Product Strategy 21.4.7.7.3. Channel Strategy 21.4.8. GSK plc. 21.4.8.1. Overview 21.4.8.2. Product Portfolio 21.4.8.3. Key Financials 21.4.8.4. SWOT Analysis 21.4.8.5. Key Developments 21.4.8.6. Sales Footprint 21.4.8.7. Strategy Overview 21.4.8.7.1. Marketing Strategy 21.4.8.7.2. Product Strategy 21.4.8.7.3. Channel Strategy 21.4.9. Aurobindo Pharma Limited 21.4.9.1. Overview 21.4.9.2. Product Portfolio 21.4.9.3. Key Financials 21.4.9.4. SWOT Analysis 21.4.9.5. Key Developments 21.4.9.6. Sales Footprint 21.4.9.7. Strategy Overview 21.4.9.7.1. Marketing Strategy 21.4.9.7.2. Product Strategy 21.4.9.7.3. Channel Strategy 21.4.10. Dr. Reddy's Laboratories 21.4.10.1. Overview 21.4.10.2. Product Portfolio 21.4.10.3. Key Financials 21.4.10.4. SWOT Analysis 21.4.10.5. Key Developments 21.4.10.6. Sales Footprint 21.4.10.7. Strategy Overview 21.4.10.7.1. Marketing Strategy 21.4.10.7.2. Product Strategy 21.4.10.7.3. Channel Strategy 21.4.11. SCYNEXIS, Inc. 21.4.11.1. Overview 21.4.11.2. Product Portfolio 21.4.11.3. Key Financials 21.4.11.4. SWOT Analysis 21.4.11.5. Key Developments 21.4.11.6. Sales Footprint 21.4.11.7. Strategy Overview 21.4.11.7.1. Marketing Strategy 21.4.11.7.2. Product Strategy 21.4.11.7.3. Channel Strategy 21.4.12. Basilea Pharmaceutica Ltd. 21.4.12.1. Overview 21.4.12.2. Product Portfolio 21.4.12.3. Key Financials 21.4.12.4. SWOT Analysis 21.4.12.5. Key Developments 21.4.12.6. Sales Footprint 21.4.12.7. Strategy Overview 21.4.12.7.1. Marketing Strategy 21.4.12.7.2. Product Strategy 21.4.12.7.3. Channel Strategy 21.4.13. Astellas Pharma Inc. 21.4.13.1. Overview 21.4.13.2. Product Portfolio 21.4.13.3. Key Financials 21.4.13.4. SWOT Analysis 21.4.13.5. Key Developments 21.4.13.6. Sales Footprint 21.4.13.7. Strategy Overview 21.4.13.7.1. Marketing Strategy 21.4.13.7.2. Product Strategy 21.4.13.7.3. Channel Strategy 21.4.14. Grupo Ferrer Internacional, S.A. 21.4.14.1. Overview 21.4.14.2. Product Portfolio 21.4.14.3. Key Financials 21.4.14.4. SWOT Analysis 21.4.14.5. Key Developments 21.4.14.6. Sales Footprint 21.4.14.7. Strategy Overview 21.4.14.7.1. Marketing Strategy 21.4.14.7.2. Product Strategy 21.4.14.7.3. Channel Strategy 21.4.15. Pacgen Life Science Corporation 21.4.15.1. Overview 21.4.15.2. Product Portfolio 21.4.15.3. Key Financials 21.4.15.4. SWOT Analysis 21.4.15.5. Key Developments 21.4.15.6. Sales Footprint 21.4.15.7. Strategy Overview 21.4.15.7.1. Marketing Strategy 21.4.15.7.2. Product Strategy 21.4.15.7.3. Channel Strategy 21.4.16. NovaDigm Therapeutics, Inc. 21.4.16.1. Overview 21.4.16.2. Product Portfolio 21.4.16.3. Key Financials 21.4.16.4. SWOT Analysis 21.4.16.5. Key Developments 21.4.16.6. Sales Footprint 21.4.16.7. Strategy Overview 21.4.16.7.1. Marketing Strategy 21.4.16.7.2. Product Strategy 21.4.16.7.3. Channel Strategy 21.4.17. Cidara Therapeutics, Inc. 21.4.17.1. Overview 21.4.17.2. Product Portfolio 21.4.17.3. Key Financials 21.4.17.4. SWOT Analysis 21.4.17.5. Key Developments 21.4.17.6. Sales Footprint 21.4.17.7. Strategy Overview 21.4.17.7.1. Marketing Strategy 21.4.17.7.2. Product Strategy 21.4.17.7.3. Channel Strategy 21.4.18. Amplyx Pharmaceuticals Inc. 21.4.18.1. Overview 21.4.18.2. Product Portfolio 21.4.18.3. Key Financials 21.4.18.4. SWOT Analysis 21.4.18.5. Key Developments 21.4.18.6. Sales Footprint 21.4.18.7. Strategy Overview 21.4.18.7.1. Marketing Strategy 21.4.18.7.2. Product Strategy 21.4.18.7.3. Channel Strategy 22. Assumptions and Acronyms Used 23. Research Methodology
Explore Healthcare Insights
View Reports
Vaginal Antifungals Market
